Effects of AHCL Insulin Pump on Glycemic Control and Psychosocial Outcomes in Pediatric Patients With Type 1 Diabetes

Inclusion Criteria: 1. The subject is age 7-19 2. The subject with one or more of the below * serum c-peptide ≤ 0.6 ng/mL at diagnosis * positive glutamic acid decarboxylase (GAD) antibody * positive islet cell antibody * positive anti-Insulin antibody * positive anti-islet Antigen-2 (IA-2) antibody 3. The subject was diagnosed with type 1 diabetes ≥ 1 year 4. The subject has been continuously treated at least for 8 weeks at the start of the study, by one of the existing insulin treatment methods \[insulin multi-injection (MDII), general insulin pump (CSII), sensor-linked insulin pump (SAP), or 770G insulin pump (HCL system)\] 5. The subject has been applied with real-time continuous glucose monitoring at least for 8 weeks at the start of the study Exclusion Criteria: 1. Any systemic treatment with drugs known to interfere with glucose metabolism within 8 weeks prior to trial 2. Subjects with underlying hematologic disorders that can affect the HbA1c levels 3. Subjects with underlying medical disorders that can affect glucose metabolism 4. Subjects with a neuropsychiatric disorder such as depression or eating disorder 5. Subjects with underlying thyroid disorders and abnormal thyroid function